Immunome's COVID-19 Cocktail Retains Neutralizing Activity Against Omicron Subvariants

  • Immunome Inc IMNM has announced that its cocktail (IMM-BCP-01) retained activity against the BA.4/5 and BA.2.12.1 subvariants in lab testing. 
  • IMM-BCP-01 is currently in Phase 1b testing in patients infected with SARS-CoV-2 and in locations where the predominant variants are BA.2.12.1, BA.4, BA.5, and BA.2.
  • Related: Immunome Shares Rise After Publishing Positive COVID-19 Antibody Cocktail Data.
  • The company expects topline data from Phase 1b study in 2H of 2022.
  • IMM-BCP-01 is a three-antibody cocktail, with each antibody having a different mechanism of action. 
  • "Further, as several existing antibody treatments lose their potency against the Omicron subvariants, IMM-BCP-01 continues to retain activity against these variants in preclinical testing, and we believe our cocktail has the potential to play a significant role in managing the pandemic," stated Purnanand Sarma, President & CEO.
  • Price Action: IMNM shares closed at $3.42 on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefsCOVID-19 Coronavirus
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!